{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:55:24Z","timestamp":1761562524683,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T00:00:00Z","timestamp":1542499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.carrev.2018.11.006","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T12:16:02Z","timestamp":1542716162000},"page":"752-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent"],"prefix":"10.1016","volume":"20","author":[{"given":"Soeren","family":"Mattke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anissa C.","family":"Dallmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bentele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2018.11.006_bb0005","first-page":"23391","author":"Patel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.11.006_bb0010","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(16)31920-1","article-title":"Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial","volume":"388","author":"von Birgelen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.11.006_bb0015","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial","volume":"384","author":"Pilgrim","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.11.006_bb0020","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.11.006_bb0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2017.08.001","article-title":"Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach","volume":"193","author":"Doros","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2018.11.006_bb0030","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2013.08.720","article-title":"Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI)","volume":"62","author":"Moussa","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.11.006_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.carrev.2012.10.006","article-title":"The prognosis of periprocedural myocardial infarction after percutaneous coronary interventions","volume":"14","author":"Zimarino","year":"2013","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2018.11.006_bb0040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/clc.20819","article-title":"Periprocedural myocardial infarction: review and classification","volume":"33","author":"Hanna","year":"2010","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.carrev.2018.11.006_bb0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCINTERVENTIONS.110.957712","article-title":"Prognostic value of isolated troponin I elevation after percutaneous coronary intervention","volume":"3","author":"Cavallini","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.11.006_bb0050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2010.07.058","article-title":"With the \u201cuniversal definition,\u201d measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention","volume":"57","author":"Lim","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.11.006_bb0055","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.11.006_bb0060","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jcin.2018.02.006","article-title":"Prognostic and practical validation of current definitions of myocardial infarction associated with percutaneous coronary intervention","volume":"11","author":"Tricoci","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.11.006_bb0065","first-page":"215","article-title":"Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention","volume":"91","author":"Ndrepepa","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.11.006_bb0070","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/eurheartj\/eht048","article-title":"Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention","volume":"34","author":"Park","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.11.006_bb0075","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCINTERVENTIONS.111.965566","article-title":"Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions","volume":"5","author":"Pervaiz","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.11.006_bb0080","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacc.2009.03.063","volume":"54","author":"Prasad","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.11.006_bb0085","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcin.2009.09.002","article-title":"Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry","volume":"2","author":"Lindsey","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.11.006_bb0090","doi-asserted-by":"crossref","first-page":"B293","DOI":"10.1016\/j.jacc.2017.09.919","article-title":"Clinical impact of periprocedural myocardial infarction according to various definitions in patients underwent percutaneous coronary intervention with drug eluting stent","volume":"70","author":"Yoon","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.11.006_bb0095","first-page":"E348","article-title":"Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: results from the CHAMPION PHOENIX ECONOMICS study","volume":"92","author":"Tamez","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.11.006_bb0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/jamacardio.2017.4771","article-title":"Association between Medicare expenditure growth and mortality rates in patients with acute myocardial infarction: a comparison from 1999 through 2014","volume":"3","author":"Likosky","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.carrev.2018.11.006_bb0105","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","article-title":"Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data","volume":"391","author":"Head","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.11.006_bb0110","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.117.028191","article-title":"India and the coronary stent market: getting the price right","volume":"135","author":"Wadhera","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.11.006_bb0115","doi-asserted-by":"crossref","first-page":"662","DOI":"10.7326\/0003-4819-151-9-200911030-00011","article-title":"Much cheaper, almost as good: decrementally cost-effective medical innovation","volume":"151","author":"Nelson","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.carrev.2018.11.006_bb0120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1377\/hlthaff.2016.1627","article-title":"National health expenditure projections, 2016\u201325: price increases, aging push sector to 20 percent of economy","volume":"36","author":"Keehan","year":"2017","journal-title":"Health Aff"},{"key":"10.1016\/j.carrev.2018.11.006_bb0125","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJMp1500445","article-title":"Setting value-based payment goals\u2014HHS efforts to improve US health care","volume":"372","author":"Burwell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.11.006_bb0130","article-title":"Medical device innovation in the era of the affordable care act: the end of sexy","volume":"6","author":"Mattke","year":"2016","journal-title":"Rand Health Q"},{"year":"2016","series-title":"Bundled payments for care improvement (BPCI) initiative: general information. 2016","author":"Medicare Cf, Services M","key":"10.1016\/j.carrev.2018.11.006_bb0135"},{"key":"10.1016\/j.carrev.2018.11.006_bb0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1377\/hlthaff.22.2.17","article-title":"The business case for quality: case studies and an analysis","volume":"22","author":"Leatherman","year":"2003","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.carrev.2018.11.006_bb0145","series-title":"Results from the PARTNER 2A and Sapien3 intermediate risk trials transcatheter cardiovascular therapeutics (TCT)","article-title":"Cost-effectiveness of transcatheter vs. surgical aortic valve replacement in intermediate risk patients","author":"Cohen","year":"2017"},{"key":"10.1016\/j.carrev.2018.11.006_bb0150","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtcvs.2017.06.020","article-title":"Cost and contribution margin of transcatheter versus surgical aortic valve replacement","volume":"154","author":"McCarthy","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.carrev.2018.11.006_bb0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJMra0912134","article-title":"Myocardial infarction due to percutaneous coronary intervention","volume":"364","author":"Prasad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.11.006_bb0160","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0140-6736(18)30528-2","article-title":"Bioresorbable polymer drug-eluting stents","volume":"391","author":"Shah","year":"2018","journal-title":"Lancet"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918304950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918304950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:15:42Z","timestamp":1761560142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838918304950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1553838918304950"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2018.11.006","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}